Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases.
Hepatic arterial floxuridine (HAI) in 35 patients with systemic fluorouracil/folinic acid-resistant colorectal liver metastases achieved a 14% partial response and 26% disease stabilization rate, with a median response duration of 7 months from onset of HAI.
Fordy
C
C
Department of Gastrointestinal Surgery, Imperial College School of Medicine, Chelsea and Westminster Hospital, London, UK.
Glover
C
C
Davies
M M
MM
Allen-Mersh
T G
TG
D015179:Colorectal Neoplasms / Q000473:pathology*; D019008:Drug Resistance, Neoplasm; D005467:Floxuridine / Q000008:administration & dosage* / Q000009:adverse effects; D005472:Fluorouracil / Q000627:therapeutic use*; D006499:Hepatic Artery; D006801:Humans; D007269:Injections, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008875:Middle Aged; D011788:Quality of Life; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
D005467:Floxuridine; D005472:Fluorouracil